Triple-negative breast cancer (TNBC) is the most malignant subtype of breast cancer (BC)
with a poor prognosis. Current treatment options are limited to surgery, adjuvant …

Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Triple negative breast cancer (TNBC) is characterized by the lack of estrogen and
progesterone receptor expression and lacks HER2 overexpression or gene amplification. It …

Triple-negative breast cancer (TNBC) encompasses a heterogeneous group of
fundamentally different diseases with different histologic, genomic, and immunologic …

Using pre-treatment gene expression, protein/phosphoprotein, and clinical data from the I-
SPY2 neoadjuvant platform trial (NCT01042379), we create alternative breast cancer …

Triple-negative breast cancer (TNBC), a specific subtype of breast cancer that does not
express estrogen receptor (ER), progesterone receptor (PR), or human epidermal growth …

Metabolic reprogramming is a hallmark of cancer. However, systematic characterizations of
metabolites in triple-negative breast cancer (TNBC) are still lacking. Our study profiled the …

Triple-negative breast cancer (TNBC) remains an unmet medical challenge. We investigated
metabolic dysregulation in TNBCs by using our multi-omics database (n= 465, the largest to …

Recent advances in spatial transcriptomics (ST) have brought unprecedented opportunities
to understand tissue organization and function in spatial context. However, it is still …

Triple-negative breast cancer (TNBC) is a collection of biologically diverse cancers
characterized by distinct transcriptional patterns, biology, and immune composition. TNBCs …